Chrysea and KaloCyte have entered into an exclusive strategic alliance intended to accelerate development and deployment of a biosynthetic red blood cell substitute for medical emergencies. According to the companies, Chrysea will apply its synthetic biology platform in conjunction with KaloCyte’s artificial red blood cell technology to address urgent blood needs when donor supply is limited.
Under the agreement, Chrysea will lead formulation and synthetic bioengineering of red blood cell analogs, while KaloCyte will focus on preclinical development and validation of the hybrid platform. The alliance is structured to combine each party’s proprietary assets and expertise.
KaloCyte is currently developing ErythroMer, a dried, shelf-stable artificial red blood cell substitute envisioned for treating life-threatening blood loss in settings where stored red blood cells are unavailable or impractical. The company claims ErythroMer has shown proof of concept in preclinical studies and could aid battlefield, disaster, and remote care scenarios.
The agreement establishes that Chrysea will have exclusive rights to certain synthetic biology applications and that KaloCyte retains rights to its core red blood cell technology. There are provisions for joint intellectual property development, regulatory coordination, and commercialization strategy.
The companies anticipate that the alliance could shorten the timeline toward clinical trials and eventual deployment of a biosynthetic blood substitute, potentially transforming emergency and trauma care.
